Cytovance Biologics to Participate in Boston’s BioProcess International Convention
August 30, 2019 08:10 ET
|
Cytovance Biologics
OKLAHOMA CITY, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the company will participate...
Avid Bioservices to Report Financial Results For First Quarter of Fiscal Year 2020 After Market Close on September 5, 2019
August 29, 2019 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices Announces Appointment of Catherine Mackey, Ph.D. to Board of Directors
July 26, 2019 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., July 26, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Erythropoietin (EPO) Drugs Market To Cross USD 12 billion by 2020 | Reports And Data
July 24, 2019 09:51 ET
|
Reports and Data
New York, July 24, 2019 (GLOBE NEWSWIRE) -- This report on the Erythropoietin (EPO) Drugs market offers an extensive analysis of the trends to estimate its growth in the near future. It provides...
Avid Bioservices Enters into Contract Manufacturing Agreements with New and Existing Customers
July 08, 2019 08:05 ET
|
Avid Bioservices, Inc
Company Signs Top Ten Global Pharmaceutical Company as New Client and Expands Relationship with Existing Biotechnology Company Customer Agreements Include Process Transfer, Process Development and...
Avid Bioservices Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2019 and Recent Developments
June 27, 2019 16:05 ET
|
Avid Bioservices, Inc
-- Achieved Fourth Quarter Revenue of $17.1 Million, an Increase of 146% Compared to Prior Year Quarter -- -- Generated Income From Continuing Operations During the Fourth Quarter of Fiscal 2019 -- ...
Cytovance® Biologics Inc. appoints Dr. Jesse McCool as Chief Technology Officer
June 27, 2019 10:38 ET
|
Cytovance Biologics
Cytovance® Biologics Inc. announced that Dr. Jesse McCool will serve the company as CTO, effective June 27, 2019 OKLAHOMA CITY, June 27, 2019 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading...
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2019 After Market Close on June 27, 2019
June 24, 2019 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., June 24, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve...
Cytovance® Biologics Inc., Completes Its Second FDA Pre-Approval Inspection (PAI) of Oklahoma City, OK Facilities
June 14, 2019 12:15 ET
|
Cytovance Biologics
OKLAHOMA CITY, June 14, 2019 (GLOBE NEWSWIRE) -- Cytovance® Biologics announced that it has received a notification letter and an Establishment Inspection Reports (EIRs) from the U.S. Food and Drug...
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
June 05, 2019 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., June 05, 2019 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve...